Business Wire

NEUSTAR

26.3.2020 09:02:06 CET | Business Wire | Press release

Share
Neustar: DDoS Attacks Increase 180% in 2019 Compared To 2018

Neustar , Inc., a global information services and technology company and leader in identity resolution, announced that its Security Operations Center (SOC) saw a 168% increase in distributed denial-of-service (DDoS) attacks in Q4 2019, compared with Q4 2018, and a 180% increase overall in 2019 vs. 2018. According to Neustar’s latest cyber threats and trends report, released today, the company saw DDoS attacks across all size categories increase in 2019, with attacks sized 5 Gbps and below seeing the largest growth. These small-scale attacks made up more than three quarters of all attacks the company mitigated on behalf of its customers in 2019.

DDoS attacks taking varied forms
In 2019, the largest threat Neustar mitigated, at 587 gigabits per second (Gbps), was 31% larger than the largest attack of 2018, while the maximum attack intensity observed in 2019, 343 million packets per second (Mpps), was 252% higher than that of the most intense attack seen in 2018. However, despite these higher peaks, the average attack size (12 Gbps) and intensity (3 Mpps) remained consistent year over year. The longest single, uninterrupted attack experienced in 2019 lasted three days, 13 hours and eight minutes.

Though the number of attacks increased significantly across all size categories, small-scale attacks (5 Gbps and below) again saw the largest growth in 2019, continuing the trend from the previous year. The combination of DDoS-for-hire and botnet rental services has made DDoS attacks much easier to execute, but the fact that perpetrators seem to be in many cases choosing to engage in small-scale attacks suggests that their goal may often be something other than taking a site completely offline.

“Large, headline-making DDoS attacks do still take place, but many cybersecurity professionals believe that smaller attacks are being used simply to degrade site performance or as a smokescreen for other forms of cybercrime, such as data theft or network infiltration, which the perpetrator can execute more easily while the target’s security team is busy fighting a DDoS attack,” said Rodney Joffe, senior vice president, senior technologist and fellow at Neustar. “Furthermore, with the current move of the bulk of the workforce globally to a work from home model, we expect to see a significant increase in DDoS attacks against VPN infrastructure. This risk makes an ‘always on’ DDoS mitigation service even more critical.”

In addition to conventional DDoS attacks, which seek to exhaust bandwidth, in 2019 Neustar also observed an increase in network protocol or state exhaustion attacks, which target network infrastructure directly. Volumetric attacks continued to proliferate as well, with attackers using new DDoS vectors such as Apple Remote Management Services, Web Services Dynamic Discovery, Ubiquiti Discovery Protocol and the Constrained Application Protocol.

Said Joffe, “During the shift to teleworking at scale, we would not be surprised to see the VPN protocol ports added to these targeted attacks.”

Two- and three-vector attacks ‘just right’ for attackers
In 2019, approximately 85% of all attacks used two or more threat vectors. That number is comparable to the 2018 figure; however, the number of attacks involving two or three vectors rose from 55% to 70%, with correspondingly fewer simple single-vector attacks and complex four- and five-vector attacks, suggesting that attackers have settled into the Goldilocks zone for attacks.

Security professionals continue to view DDoS attacks as a growing threat. According to the most recent Neustar International Security Council (NISC) survey, when asked which vectors they perceived to be increasing threats during November and December 2019, senior-level cybersecurity decision-makers cited social engineering via email most frequently (59%), followed by DDoS (58%) and ransomware (56%).

Web attacks increasing
2019 saw web attacks on the rise as well. Most companies recognise the danger that slow-loading websites pose to their business and attempt to protect them with web application firewalls. In the most recent NISC survey, 98% of respondents agreed that a WAF was an essential component of their security infrastructure. However, as more and more enterprises use multiple cloud providers, often involving a mix of public and private clouds, the need for consistent security across applications and platforms is growing.

“Web attacks can be difficult to track because some variation in the performance of websites is to be expected, but they are increasingly critical for businesses to address. One survey found 45% of consumers are less likely to make a purchase when they experience a slow loading website, and 37% are less likely to return to a retailer if they experience slow loading pages,” added Joffe.

A vendor-neutral cloud WAF, coupled with DDoS protection, can eliminate a large portion of threats, allowing enterprise application experts to focus their attention on the more specialised attacks. Continuous updates from a reliable threat feed can also deliver information on bad IPs and botnet command and control (C&C) sites before they are able to damage the network.

A complimentary copy of the Neustar 2019: The Year in Review cyber threats and trends report is available here .

-ENDS-

About Neustar
Neustar is an information services and technology company and a leader in identity resolution providing the data and technology that enables trusted connections between companies and people at the moments that matter most. Neustar offers industry-leading solutions in Marketing, Risk, Communications, Security and Registry that responsibly connect data on people, devices and locations, continuously corroborated through billions of transactions. Neustar serves more than 8,000 clients worldwide, including 60 of the Fortune 100. Learn how your company can benefit from the power of trusted connections here: https://www.home.neustar .

# # #

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye